144 related articles for article (PubMed ID: 35908474)
1. Folic acid-modified disulfiram/Zn-IRMOF3 nanoparticles for oral cancer therapy by inhibiting ALDH1A1+ cancer stem cells.
Cui J; Li W; Bu W; Liu J; Chen X; Li X; Liu C; Meng L; Chen M; Sun H; Wang J
Biomater Adv; 2022 Aug; 139():213038. PubMed ID: 35908474
[TBL] [Abstract][Full Text] [Related]
2. Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells.
Liu X; Wang L; Cui W; Yuan X; Lin L; Cao Q; Wang N; Li Y; Guo W; Zhang X; Wu C; Yang J
Oncotarget; 2016 Sep; 7(36):58516-58530. PubMed ID: 27542268
[TBL] [Abstract][Full Text] [Related]
3. Silk Fibroin-Modified Disulfiram/Zinc Oxide Nanocomposites for pH Triggered Release of Zn
Zhao YZ; Lin MT; Lan QH; Zhai YY; Xu HL; Xiao J; Kou L; Yao Q
Mol Pharm; 2020 Oct; 17(10):3857-3869. PubMed ID: 32833457
[TBL] [Abstract][Full Text] [Related]
4. Disulfiram/Copper Suppresses Cancer Stem Cell Activity in Differentiated Thyroid Cancer Cells by Inhibiting BMI1 Expression.
Ni YL; Chien PJ; Hsieh HC; Shen HT; Lee HT; Chen SM; Chang WW
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362068
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic effect of disulfiram/copper on human cervical cancer cell lines and LGR5-positive cancer stem-like cells.
Cao HZ; Yang WT; Zheng PS
BMC Cancer; 2022 May; 22(1):521. PubMed ID: 35534815
[TBL] [Abstract][Full Text] [Related]
6. Disulfiram's Anticancer Activity: Evidence and Mechanisms.
Jiao Y; Hannafon BN; Ding WQ
Anticancer Agents Med Chem; 2016; 16(11):1378-1384. PubMed ID: 27141876
[TBL] [Abstract][Full Text] [Related]
7. Novel Disulfiram Derivatives as ALDH1a1-Selective Inhibitors.
Omran Z
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056791
[TBL] [Abstract][Full Text] [Related]
8. Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer.
Kim JY; Cho Y; Oh E; Lee N; An H; Sung D; Cho TM; Seo JH
Cancer Lett; 2016 Aug; 379(1):39-48. PubMed ID: 27238567
[TBL] [Abstract][Full Text] [Related]
9. Soybean lecithin stabilizes disulfiram nanosuspensions with a high drug-loading content: remarkably improved antitumor efficacy.
Li H; Liu B; Ao H; Fu J; Wang Y; Feng Y; Guo Y; Wang X
J Nanobiotechnology; 2020 Jan; 18(1):4. PubMed ID: 31907045
[TBL] [Abstract][Full Text] [Related]
10. Repositioning disulfiram as a radiosensitizer against atypical teratoid/rhabdoid tumor.
Lee YE; Choi SA; Kwack PA; Kim HJ; Kim IH; Wang KC; Phi JH; Lee JY; Chong S; Park SH; Park KD; Hwang DW; Joo KM; Kim SK
Neuro Oncol; 2017 Aug; 19(8):1079-1087. PubMed ID: 28340172
[TBL] [Abstract][Full Text] [Related]
11. Targeting cancer stem cells by disulfiram and copper sensitizes radioresistant chondrosarcoma to radiation.
Wang K; Michelakos T; Wang B; Shang Z; DeLeo AB; Duan Z; Hornicek FJ; Schwab JH; Wang X
Cancer Lett; 2021 May; 505():37-48. PubMed ID: 33582212
[TBL] [Abstract][Full Text] [Related]
12. Buffet-style Cu(II) for enhance disulfiram-based cancer therapy.
Zhao L; Wang X; Lou H; Jiang M; Wu X; Qin J; Zhang J; Guan X; Li W; Zhang W; Ma J
J Colloid Interface Sci; 2022 Oct; 624():734-746. PubMed ID: 35696791
[TBL] [Abstract][Full Text] [Related]
13. Differential Cytotoxicity Mechanisms of Copper Complexed with Disulfiram in Oral Cancer Cells.
Chen SY; Chang YL; Liu ST; Chen GS; Lee SP; Huang SM
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33918312
[TBL] [Abstract][Full Text] [Related]
14. A novel reporter construct for screening small molecule inhibitors that specifically target self-renewing cancer cells.
Shanmugam G; Mohan A; Kumari K; Louis JM; Soumya Krishnan U; Balagopal PG; George NA; Sebastian P; Maliekal TT
Exp Cell Res; 2019 Oct; 383(2):111551. PubMed ID: 31401066
[TBL] [Abstract][Full Text] [Related]
15. Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.
Yang Z; Guo F; Albers AE; Sehouli J; Kaufmann AM
Biomed Pharmacother; 2019 May; 113():108727. PubMed ID: 30870721
[TBL] [Abstract][Full Text] [Related]
16. Disulfiram: a novel repurposed drug for cancer therapy.
Lu C; Li X; Ren Y; Zhang X
Cancer Chemother Pharmacol; 2021 Feb; 87(2):159-172. PubMed ID: 33426580
[TBL] [Abstract][Full Text] [Related]
17. Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid/rhabdoid tumors.
Choi SA; Choi JW; Wang KC; Phi JH; Lee JY; Park KD; Eum D; Park SH; Kim IH; Kim SK
Neuro Oncol; 2015 Jun; 17(6):810-21. PubMed ID: 25378634
[TBL] [Abstract][Full Text] [Related]
18. The interaction of disulfiram and H
Read E; Milford J; Zhu J; Wu L; Bilodeau M; Yang G
Toxicol Appl Pharmacol; 2021 Sep; 426():115642. PubMed ID: 34242567
[TBL] [Abstract][Full Text] [Related]
19. Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells.
Kim YJ; Kim JY; Lee N; Oh E; Sung D; Cho TM; Seo JH
Biochem Biophys Res Commun; 2017 May; 486(4):1069-1076. PubMed ID: 28373070
[TBL] [Abstract][Full Text] [Related]
20. Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.
Huang H; Liao Y; Liu N; Hua X; Cai J; Yang C; Long H; Zhao C; Chen X; Lan X; Zang D; Wu J; Li X; Shi X; Wang X; Liu J
Oncotarget; 2016 Jan; 7(3):2796-808. PubMed ID: 26625200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
